<DOC>
	<DOCNO>NCT00003119</DOCNO>
	<brief_summary>RATIONALE : Surgery alone may effective treat child neuroblastoma . PURPOSE : Phase III trial study effectiveness surgery alone treat child neuroblastoma .</brief_summary>
	<brief_title>Surgery Treating Children With Neuroblastoma</brief_title>
	<detailed_description>OBJECTIVES : - To determine asymptomatic patient low-risk neuroblastoma treat surgery alone 3-year survival rate 95 % . - Estimate response 3-year event-free survival rate symptomatic patient treat chemotherapy . - Estimate event-free survival overall survival rate patient relapse progress initial treatment surgery alone . - Determine acute chronic toxic effect associate treat low-risk neuroblastoma surgery alone surgery chemotherapy . OUTLINE : This multicenter study . Patients stratify accord disease stage , MYCN status , age , histology . Patients undergo primary tumor resection biopsy regional node . Patients least 50 % tumor resect follow monthly 3 month , every 3 month 9 month , every 6 month one year , annually thereafter . Regimen I - Patients clinically symptomatic ( e.g. , respiratory distress , spinal cord compromise without neurologic deficit , inferior vena cava compression renal bowel ischemia , intractable vomit due gastrointestinal obstruction , genitourinary obstruction , coagulopathy ) low-risk neuroblastoma le 50 % primary tumor resect receive 4 different course chemotherapy . - Course 1 : Patients receive carboplatin IV 1 hour follow etoposide IV 2 hour day 0 etoposide day 1 2 . - Course 2 : Patients receive carboplatin IV 1 hour , cyclophosphamide IV 1 hour , doxorubicin IV 15-60 minute day 1 . - Course 3 : Patients receive cyclophosphamide IV 1 hour follow etoposide IV 2 hour day 0 etoposide day 1 2 . - Course 4 : Patients receive carboplatin IV 1 hour etoposide IV 2 hour follow doxorubicin IV 15-60 minute day 0 etoposide day 1 2 . Regimen II - Patients progress recur unfavorable biology intermediate-risk disease receive additional 4 course chemotherapy . - Course 5 : Patients receive treatment course 3 . - Course 6 : Patients receive treatment course 2 . - Course 7 : Patients receive treatment course 1 . - Course 8 : Patients receive cyclophosphamide IV 1 hour follow doxorubicin IV 15-60 minute day 1 . All infant 60 day age receive filgrastim ( G-CSF ) sargramostim ( GM-CSF ) subcutaneously begin 24 36 hour chemotherapy continue blood count recover . Courses regimens repeat every 3 week absence unacceptable toxicity . Patients risk symptomatic spinal cord compression may also receive chemotherapy . Patients experience progressive recurrent disease observation undergo repeat surgery and/or chemotherapy . Patients clinically symptomatic disease may also undergo radiotherapy response chemotherapy rapid . Patients follow every 2 month 1 year , every 3 month 1 year , every 6 month 1 year , annually thereafter . PROJECTED ACCRUAL : A total 820 patient accrue study within 4 year .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven lowrisk neuroblastoma ( exclude ganglioneuroma ) International Neuroblastoma Staging System ( INSS ) stage 1 patient INSS stage 2A 2B patient less 365 day age INSS stage 2A 2B tumor nonamplified MYCN Shimada histology patient age 1 20 year INSS stage 2A 2B tumor amplify MYCN Shimada favorable histology patient age 1 20 year INSS stage 4S tumor nonamplified MYCN , Shimada favorable histology , DNA index equal 1 patient less 365 day age Immediate chemotherapy allow prior biopsy patient intradural extension and/or emergent paresis biopsy perform within 96 hour Must abnormal organ function unless due neuroblastoma Concurrent registration companion biology study ( protocol COGANBL00B1 ) successor PATIENT CHARACTERISTICS : Age : Under 21 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin le 1.5 time normal SGOT SGPT less 2.5 time normal Renal : Creatinine le 1.5 time normal Cardiovascular : Shortening fraction great 27 % echocardiogram OR Ejection fraction great 47 % radionuclide angiogram PRIOR CONCURRENT THERAPY : Biologic therapy : No prior immunotherapy Chemotherapy : See Disease Characteristics Endocrine therapy : No prior hormonal therapy Radiotherapy : No prior radiotherapy Surgery : Prior surgery allow Other : No prior therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>localize resectable neuroblastoma</keyword>
	<keyword>stage 4S neuroblastoma</keyword>
</DOC>